Open AccessDBC1 does not function as a negative regulator of SIRT1 in liver cancer
Author(s) -
Hyun Jin Bae,
Young Gyoon Chang,
Ji Heon Noh,
Jeong Kyu Kim,
Jung Woo Eun,
Kwang Hwa Jung,
Min Kim,
Qingyu Shen,
Young Min Ahn,
So Hee Kwon,
Won Sang Park,
Jung Young Lee,
Suk Woo Nam
Publication year - 2012
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2012.875
Subject(s) - liver cancer , cancer research , cancer , oncogene , regulator , biology , cancer cell , sirtuin 1 , lung cancer , hepatocellular carcinoma , cell cycle , apoptosis , medicine , downregulation and upregulation , biochemistry , gene , genetics
The putative tumor suppressor, DBC1 (deleted in breast cancer-1), was recently found to negatively regulate SIRT1 in vitro and in vivo, but the mechanism whereby DBC1 regulates SIRT1 in liver cancer remains to be elucidated. In this study, it was found that although the expression of DBC1 and SIRT1 was not aberrantly regulated in a large cohort of human hepatocellular carcinoma (HCC) patients, these proteins were highly overexpressed in a subset of HCC tissues compared with surrounding non-cancer tissues. In liver cancer, DBC1 and SIRT1 were found to be positively correlated. Inactivation of DBC1 or SIRT1 reduced SNU-182 (a liver cancer cell line) proliferation as determined by MTT viability assays. Notably, although DBC1 functions as a negative regulator of SIRT1 in A549 lung cancer cells since it suppresses the deacetylase activity of the p53 protein, it did not affect the p53 deacetylase activity of SIRT1 in SNU-182 cells. Taken together, we conclude that DBC1 is associated with SIRT1 in HCC, but that it does not inhibit SIRT1.